 |
|
|
| |
Pharmacokinetics of oral islatravir plus lenacapavir given once weekly in an open-label, active-controlled, phase 2 study of virologically suppressed people living with HIV-1
|
| |
| |
HIV Drug Therapy Glasgow; Glasgow, United Kingdom; November 10-13, 2024
Diane Longo1; Gillian Gillespie1*; Michelle Pham1; Stephanie Klopfer1; Haeyoung Zhang2; Ramesh Palaparthy2; Angela S. Y. Liu2; Randolph P. Matthews1; Cyril Llamoso1; Elizabeth G. Rhee1; S. Aubrey Stoch1; Dhananjay D. Marathe2; Ryan Vargo1
1Merck & Co., Inc., Rahway, NJ, USA;
2Gilead Sciences, Foster City, CA, USA
*Presenting author
|
| |
|
|
|
|
|
